evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

67 questions · 68 findings · 7 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 27 · 39.7%GRADE not reported 3 · 4.4%Very low 0 · 0%Low 9 · 13.2%Moderate 14 · 20.6%High 15 · 22.1%

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in remission (number of patients with remission) compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Durable remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in durable remission compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Major relapse · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in major relapse compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Disease flare · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in disease flare compared with standard therapy with placebo (moderate certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Any adverse event · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any adverse event compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Any severe or serious AE (grade 3, 4 or 5) · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any severe or serious AE (grade 3, 4 or 5) compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Withdrawals due to adverse events · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy may leads to higher any withdrawals due to AE compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

MortalityNumber of participants: 285(2 RCTs) WGET 2005 · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in mortalityNumber of participants: 285(2 RCTs) WGET 2005 compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Any systemic treatment vs placebo

Etanercept · people with chronic plaque psoriasis

Any systemic treatment probably leads to higher etanercept compared with placebo (moderate certainty).

2 findings from 1 review

Intervention not reported

ACR50 American College of Rheumatology 50% improvement criteria · participants with rheumatoid arthritis and with a partial response to DMARDs

The intervention probably leads to higher ACR50 American College of Rheumatology 50% improvement criteria (moderate certainty).

1 finding from 1 review

Intervention not reported

Reduction in disability score Health Assessment Questionnaire (mean improvement from baseline). Scale from: 0 to 3 · participants with rheumatoid arthritis and with partial response to MTX
1 finding from 1 review

Intervention not reported

Radiographic progression Total Sharp Score · participants with rheumatoid arthritis and with partial response to MTX
1 finding from 1 review

Intervention not reported

Withdrawals due to adverse events · participants with rheumatoid arthritis and with partial response to MTX

The intervention showed no clear difference in withdrawals due to adverse events (moderate certainty).

1 finding from 1 review

Intervention not reported

Serious adverse events · participants with rheumatoid arthritis and with partial response to MTX

The intervention showed no clear difference in serious adverse events (moderate certainty).

1 finding from 1 review

Intervention not reported

Serious infections · participants with rheumatoid arthritis and with partial response to MTX
1 finding from 1 review

Intervention not reported

Serious infections · participants with rheumatoid arthritis

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Outcome: ACR50 ‐ American College of Rheumatology Improvement Criteria · participants with rheumatoid arthritis

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Remission Achievement of disease activity score < 2.6 · participants with rheumatoid arthritis and with a partial response to DMARDs

The intervention leads to higher remission Achievement of disease activity score < 2.6 (high certainty).

1 finding from 1 review